Neuropathy News and Research

RSS

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.

6 Oct 2011

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo BioSciences, Inc. today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.

3 Oct 2011

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.

29 Sep 2011

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Cannabidiol—a compound derived from marijuana—may be a promising new treatment to prevent the development of painful neuropathy in patients receiving the chemotherapy drug paclitaxel, according to animal experiments reported in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Sep 2011

New research has potential to alleviate side effects of cancer treatments

Beth Faiman MSN, CNP, a doctoral candidate at the Frances Payne Bolton School of Nursing at Case Western Reserve University, is studying whether an over-the-counter medication could ease chemotherapy side effects for people with blood and bone marrow cancers.

20 Sep 2011

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Thanks to greater awareness, earlier detection and improving therapeutic agents, people with cancer are living longer than ever before. One of the consequences of living longer is the symptom burden of cancer survivorship, which may have a substantial impact on quality of life for many survivors. One such burden is the pain syndromes resulting from cancer treatments.

17 Sep 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Diamyd Medical AB with collaborators has received a three million dollar grant from the US National Institutes of Health to develop the Company's patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy.

12 Sep 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar Therapeutics announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.

12 Sep 2011

New Diabetes Care article helps to identify and treat Charcot foot

Robert Winkler says he limped around on his painful left foot for six months, suffering unnecessarily from a misdiagnosis by a physician who didn't know about the symptoms and treatments for Charcot foot, a form of localized osteoporosis linked to diabetes that causes the bones to soften and break, often resulting in amputation.

2 Sep 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Seven research teams across the U.S. to develop new drugs for nervous system disorders

The National Institutes of Health has made awards to investigators across the United States for an ambitious set of projects seeking to develop new drugs for disorders of the nervous system.

19 Aug 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Researchers identify genes that play a key role in pain perception

By working with individuals suffering from a severe disorder that causes sensory neurons to degenerate, researchers at the University of Montreal Hospital and CHU Sainte-Justine Hospital have discovered how a specific genetic mutation causes their patients' condition, which in turn has revealed more information about the mechanisms in our bodies which enable us to sense pain.

5 Aug 2011

VIB researchers develop mouse model for Charcot-Marie-Tooth neuropathy

VIB researchers have developed a mouse model for Charcot-Marie-Tooth (CMT) neuropathy, a hereditary disease of the peripheral nervous system.

3 Aug 2011

Lesser toe deformities should be treated early: Literature review

While deformities of the lesser toes can be very painful, there are numerous surgical and nonsurgical treatments for these conditions that are usually quite effective.

2 Aug 2011

Neuropathy News and Research

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

New research has potential to alleviate side effects of cancer treatments

DARA's KRN5500 meets primary end-points in Phase II study for chemotherapy-induced neuropathic pain

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Diamyd receives NIH grant to develop NTDDS for Chemotherapy Induced Peripheral Neuropathy

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

New Diabetes Care article helps to identify and treat Charcot foot

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Seven research teams across the U.S. to develop new drugs for nervous system disorders

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

FDA approves Gilead's Complera for treatment of HIV-1 infection

Researchers identify genes that play a key role in pain perception

VIB researchers develop mouse model for Charcot-Marie-Tooth neuropathy

Lesser toe deformities should be treated early: Literature review

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News